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A B S T R A C T
Cryptogenic stroke and migraine headache are disorders which most commonly af-
fect persons younger than 55 years of age. In recent years these disorders have been 
found to have a strong association with inter-atrial cardiac defects, such as patent 
foramen ovale and atrial septal defect, and support the pathophysiological mechanism 
of paradoxical embolism with a right-to-left shunt. With the evolution of technology, 
magnetic resonance imaging has more clearly defined cryptogenic stroke, and per-
cutaneous cardiac interventional devices have offered a simplified approach to clo-
sure of inter-atrial cardiac defects. Nevertheless, the evidence-based data of which 
sub-populations of patients with cryptogenic stroke or migraine headache will benefit 
from closure of inter-atrial cardiac defects is just being defined. This review offers a 
clinical cardiologist’s viewpoint of these developments.
C R Y P T O G E N I C  S T R O K E
T H E  C L I N I C A L  P R O B L E M
Stroke is a leading cause of death and long-term disability worldwide. Eighty-five 
percent of strokes are ischemic, and most ischemic strokes occur in persons older 
than 65 years of age in tandem with the development of atherosclerosis. Although a 
minority of ischemic strokes in the community affect younger adults, as many as half 
the patients referred to tertiary care centers are younger than 65 years of age, and up 
to 12% are younger than 45 years.1 Young patients with ischemic stroke often have 
few, if any, risk factors for atherosclerosis. Initial evaluation of the cerebral arteries 
is essential but frequently unrevealing, and thus in many cases the focus must shift to 
the detection of potential cardiac sources of embolism that are commonly associated 
with, and that may cause, unexplained stroke in young persons.2
In as many as 43% of affected young adults, strokes are cryptogenic (i.e., they do 
not have a definite cause despite extensive evaluation).1 This brain infarction which is 
commonly revealed by a magnetic resonance imaging (MRI) abnormality without an 
etiology is the essence of a cryptogenic stroke. The most prevalent potential source 
of cardioembolism in young adults (<55 years) with cryptogenic stroke is a patent 
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foramen ovale (PFO), which is detected in more than half 
of such persons undergoing evaluation.3 On the other hand, 
cryptogenic strokes in the middle-aged and elderly (>55years) 
patients account for approximately one-third of ischemic 
strokes, and have most commonly been associated with aortic 
arch atheromatous plaques.4,5 Transesophageal echocardio-
graphic (TEE) detection of plaques ≥4 mm proximal to the 
ostium of the left subclavian artery in the elderly have been 
found to be significant predictors of new brain infarcts and 
other vascular events.4,5
This presentation focuses on the majority of brain inf-
arctions which occur in the young and have been found to 
be associated with interatrial septal abnormalities [PFO, 
atrial septal defect (ASD) or atrial septal aneurysm (ASA)], 
cardiac valvulopathies, dissections of extracranial arteries or 
hypercoagulable states.6 Whereas the latter conditions render 
a definable etiology of stroke, there remains in approximately 
50 to 60 % of patients younger than 55 years of age (despite a 
thorough evaluation) an unknown cause. In these cryptogenic 
stroke patients, the presence of a PFO or ASD has been 
found by TEE in approximately 40 to 50 % of patients, and 
strongly suggests that the pathologic mechanism of disease is 
paradoxical embolism.6,7
PA T E N T  F O R A M E N  O VA L E  A N D  C R Y P T O G E N I C 
S T R O K E
A PFO has been defined by autopsy series to occur in ~25 
to 27 % of the population, and is large (0.6 to 2.0 cm) in 6%.7,8 
PFO frequency and size have been found to vary by age and 
size, and may be an important factor in acting as a conduit in 
paradoxical embolism.7,8 Cryptogenic stroke patients appear 
to have larger PFOs than those of control patients.8
In the recent PFO in Cryptogenic Stroke Study (PICSS), it 
has also been shown that large PFOs were significantly more 
prevalent among cryptogenic stroke patients compared with 
those with known cause of stroke.9 Additionally, stroke patients 
with larger PFOs have brain imaging findings suggestive of an 
embolic mechanism10 and PFO size may be an independent 
risk factor for recurrent cerebrovascular events.8
O T H E R  FA C T O R S  R E L A T E D  T O  P F O  
A N D  C R Y P T O G E N I C  S T R O K E
The prevalence of atrial septal aneurysm (ASA) is greater 
among patients with embolic events. It is also well known that 
ASA is associated with PFO, with ~60% of patients with ASA 
having a PFO.11 Additionally, the PFOs seen in the presence 
of ASA tend to be large compared with those seen without 
associated ASA.12 Thus, the association of ASA with embolic 
events is likely based on the high prevalence of large PFOs. 
Because an ASA is usually highly mobile, protruding from 
right to left atrium, it is unlikely that a thrombus forms in situ 
in the ASA itself.
The eustachian valve is a membrane-like structure in the 
right atrium. Among adults, a eustachian valve can cause a 
significant right-to-left shunt in the presence of a PFO or ASD 
by directing the blood flow pattern to the interatrial defect.13 
These prominent eustachian valves have been found more 
commonly in patients with presumed paradoxical embolism 
than in control patients.13 The presence of Chiari’s network 
and filamentous strands which occur in the right atrium in 
some patients, have also been defined to have an association 
with PFO.14
The hemodynamics which favor right-to-left shunting 
through an interatrial communication, also play a role in deter-
mining the probability of paradoxical embolization in patients 
with cryptogenic stroke. Whereas aging with its changes in 
right atrial pressure is an infrequent confounding factor not 
found to be significantly associated with cryptogenic strokes, 
the patient who presents with pulmonary embolus, right ven-
tricular infarction or severe tricuspid regurgitation will have 
an elevated right-to-left shunt through a PFO.7
More recently, pelvic vein thrombi have been reported 
to be found in young cryptogenic stroke patients compared 
to those with known causes of stroke.15 Since these veins 
are rarely studied in such patients, their consideration as 
a contributing factor must also be borne in mind. Patients 
with a hypercoaguable state have also been defined within 
the cohorts of cryptogenic stroke.16 The higher frequency of 
prothrombotic states associated with G20210A and factor V 
Leiden mutations in patients with cyrptogenic stroke and PFO 
suggests a contributory mechanism to the suspected paradoxi-
cal embolization.16
R E C U R R E N T  S T R O K E  P R E V E N T I O N  
A N D  T R E A T M E N T
The focus of medical treatment for cryptogenic stroke is 
to prevent recurrent events. Such therapy has employed anti-
thrombotic (warfarin and antiplatelet) regimens, and surgical 
and device closures of PFO or ASD. Whereas a summary of 
medical therapy studies following cryptogenic stroke patients 
(N=943) for a mean duration of 33 months found the annual 
rate of recurrent stroke to be 1.98% and stroke or death at 3.12 
%, these studies are confounded by different age groups.7 In 
a retrospective analysis from the PFO in Cryptogenic Stroke 
Study (PICSS), the presence of a PFO in younger cryptogenic 
stroke patients did not seem to increase the risk of adverse 
events, but significantly increased events in older patients.17 
Thus, age is an important confounding factor. Only one study 
has randomized patients to warfarin or aspirin therapy, and 
found no difference in event rates.9 There exists no randomized 
controlled prospective trials examining the effects of aspirin 
and/or clopidogrel versus warfarin in cryptogenic stroke pa-
tients, and although such therapy is commonly employed, de-
finitive data do not exist. Because of the known major bleeding 
risk of warfarin at 1 to 2 % annually, and minor bleeding risk 
of 10 to 20 %, empiric therapy today has commonly employed 
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aspirin and clopidogrel strategies.7
Surgical closure studies of PFO and ASD in the literature 
have examined less that 200 patients and have defined the an-
nual rate of recurrent stroke as <0.34% and stroke or death 
<1.0%.7 Nevertheless, the development of percutaneous clo-
sure devices have seemingly obviated the need for surgery with 
its attendant morbidity and cost, even considering minimally 
invasive techniques.18 Thus, attention has focused on the use of 
transcatheter closure devices (e.g Amplatzer, CardioSeal and 
StarFlex devices) to occlude the interatrial communication of 
PFO and ASDs. These devices in over 1400 patients followed 
showed an annual rate of recurrent stroke of 0.19% and stroke 
or death of 1.15%.7 Complications from such devices include 
major events such as death, hemorrhage, cardiac tamponade 
and fatal pulmonary emboli, and are estimated to occur in 
~1.5% of patients.7 It is intuitive that this latter figure is highly 
dependent on the emergence of varied new and sub-optimal 
devices, as well as lack of experience in some operators. Mi-
nor complications of atrial arrhythmias, device embolization, 
device thrombosis, ECG changes, and arteriovenous fistula 
formation are reported in 7.9%.19
There are 3 ongoing randomized studies in the United 
States comparing the efficacy of percutaneous closure with 
medical therapy in cryptogenic stroke patients. The Ran-
domized Evaluation of Recurrent Stroke Comparing PFO 
Closure to Established Current Standard of Care Treatment 
(RESPECT) trial randomizes cryptogenic stroke patients 
with PFO to percutaneous closure with an Amplatzer device 
or medical therapy (antiplatelet or warfarin at the enrolling 
physician’s discretion). The CLOSURE I trial randomizes 
patients with stroke or transient ischemic attack (TIA) thought 
to be due to paradoxical embolization to percutaneous closure 
with the STARFlex septal occluder or medical therapy (aspirin 
and/or warfarin at the enrolling physician’s discretion). The 
Cardia PFO trial randomizes patients to PFO closure using its 
PFO closure device or warfarin. The Amplatzer device is also 
used in Europe and Australia in the Patent Foramen Ovale and 
Cryptogenic Embolism PC-trial. This study randomizes cryp-
togenic stroke patients with PFO to device closure or medical 
therapy (antiplatelet or warfarin at the enrolling physician’s 
discretion). Finally, the CLOSEUP (Closure Using Premere) 
trial will be using a new PFO closure device (Premere) and 
similarly randomize patients to percutaneous device closure 
or medical therapy. Of note, in all trials, patients randomized 
to the device arm also receive medical therapy for a variable 
period of time, in some cases for the study duration. These 
studies seek to demonstrate the superiority of device plus 
medical therapy over medical therapy alone.
T H E  C L I N I C I A N ’ S  V I E W
Cryptogenic stroke (i.e. without apparent cause or source) 
is predominantly a disorder of middle-aged and younger per-
sons (<55 years). When it occurs in older individuals (>55 
years) a search for aortic arch atheroma and arteriosclerotic 
disease is indicated. But the vast majority of such strokes occur 
in younger individuals, where the most prevalent suspected 
etiology is the mechanism of paradoxical embolism through 
an interatrial abnormality (PFO or ASD). Investigation by 
transcranial Doppler or TEE with saline venous infusion 
(bubble study) are the diagnostic methods of choice to lead 
the investigation. Definition of the atrial anatomy and other 
factors contribute to the probability of the suspected paradoxi-
cal embolism. Treatment with modern anti-thrombotic therapy 
(i.e. aspirin and clopidogrel) currently seems warranted as a 
first-line of defense to prevent recurrent stroke, particularly in 
view of the long-term cost and morbidity of warfarin therapy 
in this predominantly young patient group. Subsequently, 
second-line referral of patients with large PFOs, and identified 
atrial abnormalities (i.e. large defects, prominent Eustachian 
valve or Chiari network or filamentous strands or ASA) for 
transcatheter closure to an experienced center seems indicated 
according to the results of non-randomized studies and by 
expert consensus. Lastly, referral for participation in prospec-
tive randomized clinical trials employing both medical therapy 
and closure devices should be supported for those individuals 
whose clinical features do not predominantly argue for the 
mechanism of paradoxical embolization to help define the 
best treatment to prevent recurrent stroke.
M I G R A I N E  H E A D A C H E
T H E  C L I N I C A L  P R O B L E M
Migraine is a common disorder, with a one-year prevalence 
rate in Americans of approximately 13% (18% of women and 
6 to 7% of men).20 Migraine is thus about three times more 
common in women than men. It tends to run in families, and 
typically it is a disorder of young, primarily healthy women. 
Migraine without aura is the most common type, accounting 
for approximately 80% of all migraine sufferers. Nonpharma-
cologic modalities, such as regular exercise, relaxation, stress 
management, biofeedback, ice massage, physical therapy 
techniques, and others may play an important role in both 
the prophylactic and abortive treatment of migraine, although 
the data are somewhat limited.21 Migraine is thought to have a 
polygenetic and multifactorial etiology.22 No consistent genetic 
basis has been established for migraine, with the exception of 
familial hemiplegic migraine.
T H E  PA T H O P H Y S I O L O G Y
No single theory or hypothesis can explain all of the phe-
nomena that occur with migraine. The once popular vascular 
theory of migraine, which suggested that vascular headaches 
such as migraine and cluster headaches were caused by the 
dilatation of blood vessels, while the aura of migraine resulted 
from vasoconstriction, is no longer considered viable in its 
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original form. Nevertheless, it may well be that vasodilatation 
plays an important role in the severe throbbing head pain that 
is characteristic of migraine; vasodilatation itself is probably 
an epiphenomenon, resulting from instability in the central 
neurovascular control mechanism.23
The current state of knowledge in this field suggests that a 
primary neuronal dysfunction leads to a sequence of changes 
intracranially and extracranially that account for migraine, 
including the three phases of prodrome, aura, and headache.24 
Individuals prone to migraine have a genetic migrainous 
threshold that renders them susceptible to an acute migraine 
attack depending upon the balance between excitation and 
inhibition at various levels of the nervous system. Both genetic 
and environmental factors are important.25
Serotonin (released from brainstem serotonergic nuclei) 
also plays an important role in the pathogenesis of migraine; 
this is probably mediated via its direct action upon the cranial 
vasculature, through its role in central pain control pathways 
and through cerebral cortical projections of brainstem sero-
tonergic nuclei.26 The exact mechanism of serotonin action 
remains obscure. A decline in serotonergic function has been 
noted during acute migraine attacks, resulting in vasodilation 
of cranial vessels and sensitization of meningeal afferents of 
the trigeminal nerve.27 Between attacks, patients who have 
migraine without aura appear to have increased brain serot-
onin synthesis.28
More recently, migraine with aura has been linked to 
right-to-left cardiac shunts, usually in the setting of a patent 
foramen ovale (PFO) or, much less often, an atrial septal de-
fect (ASD).29,30 In a study of 581 cryptogenic stroke patients, 
migraine was more common in the 46% of patients with PFO 
than those without PFO (27% versus 14%).30 In other reports, 
patients with migraine associated with aura were more likely 
to have a PFO than patients with migraine without aura or 
controls.31,32
The mechanism of the association between right-to-left 
cardiac shunt and migraine is not known. One theory is that 
the venous circulation contains vasoactive substances (e.g. 
serotonin) capable of triggering migraine; these are normally 
inactivated in the lungs but gain access to the cranial circulation 
in the presence of a right-to-left shunt.24 However, a recently 
favored hypothesis is that the existence of a right-to-left shunt 
provides a pathway for paradoxical embolism of microemboli 
(1 to 3 mm) and subsequent cerebral ischemia, which in turn 
triggers migraine. This hypothesis is aided by a recent study 
which demonstrated a 13.7-fold higher incidence of MRI le-
sions in migraine patients with aura than in controls.34
Moreover, recent clinical studies of cryptogenic stroke 
patients with migraine, strongly attest to the benefit of PFO or 
ASD closure in the resolution or improvement of symptoms in 
migraine patients.30,32,33 Migraine headache has been defined 
in 35 to 42 % of cryptogenic stroke patients, with as many 
as two-thirds of those patients experiencing migraine with 
aura.30,33 Complete resolution of migraine symptoms following 
closure of the PFO or ASD in patients with migraine and aura 
has been found to occur in 56 to 75 % of such patients.30,33 The 
association of migraine and PFO is even stronger in patients 
with PFO and atrial septal aneurysm.29
In the recently reported Migraine Intervention with Star-
flex Technology (MIST) trial,35 patients, aged 18 to 60 years, 
with a one-year documented history of migraine with aura 
occurring at least 5 times per month were studied. Additional 
selection criteria of failed medication from two classes of 
prophylactic medications and at least 7 days free of headache 
per month were required. Screening of 432 patients resulted in 
identifying 147 patients, 84% women, mean age 44 years, who 
were randomized to PFO closure with the STARFlex Septal 
Repair Implant (n=74) or a sham procedure (control group; 
n=73). Patients but not physicians were blinded to randomized 
treatment. Patients were followed for 6 months regarding 
migraine frequency and severity, during which patients were 
FIGURE 1. Percutaneous Closure of a Patent Foramen Ovale. 
With use of a femoral approach, a transvenous sheath is ad-
vanced across the foramen into the left atrium, where a folded 
disk is expanded and pulled back, apposing the primum and se-
cundum septa closed. This step is followed by deployment of a 
right-sided disk, at which time the two-disk device is released. 
Clopidogrel and aspirin are recommended for a period of three 
months to prevent thrombus formation on the device, with as-
pirin therapy continued for an additional three months, when 
endothelialization is complete. Antibiotic prophylaxis for six 
months is recommended. Complete late closure of the foramen 
has been reported in 80 to 95% of patients. [Reproduced with 
permission from N Engl J Med 2005; 353:2368 (ref. 6)].
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treated with aspirin and clopidogrel for the first 3 months. Ex-
clusions from the trial included migraine medication overuse, 
prior stroke/TIA and cardiac anomaly contraindications.
The principal findings showed among the 432 patients 
screened in the trial, 60.2% had an atrial right-to-left shunt, 
much higher than typically found in the general population (i.e. 
~27%). A large atrial shunt was present in 37.7% of patients, 
with a small shunt in 16.7% and no shunt in 39.8%.35 The mean 
diameter of PFO in the trial was 9.21 mm. There was no dif-
ference between groups in the primary endpoint of complete 
cessation of migraines, with 3 patients in each group meeting 
this criterion. Reduction in headache-days by at least 50% 
occurred more frequently in the PFO closure group (42% vs 
23%, p=0.038). The reduction in headache burden, defined 
as the frequency x duration of headache, was greater (37% vs 
14%) in the PFO closure group (from 136.1 at baseline to 86.06 
at follow-up, p=0.033 in PFO group; from 116.8 at baseline 
to 96.32 at follow-up, p=NS in control group). Thus among 
migraine sufferers screened for enrollment in the trial, PFO 
closure was not associated with a difference in total migraine 
resolution compared with a sham procedure. While the pri-
mary endpoint did not differ by treatment group, reduction of 
headache frequency by 50% occurred more frequently in the 
PFO group. This endpoint is not as rigid as the total elimina-
tion endpoint but would be clinically important to patients ex-
periencing migraines. The on-going MIST II trial will evaluate 
PFO closure for migraine improvement but will incorporate a 
longer patient follow-up, with the hypothesis that much of the 
benefit may emerge later following PFO closure.
T H E  C L I N I C I A N ’ S  V I E W
Whereas medical therapy of migraine is beyond the scope 
of this presentation, in the patient with migraine, the possibility 
of a PFO or ASD with paradoxical embolism must be strongly 
considered as a pathologic mechanism. This is particularly 
true when the migraine is accompanied by an aura. Diagnos-
tic studies should include a transcranial Doppler study with 
venous saline injection (bubble study), or a transesophageal 
echocardiogram with venous saline injection (preferably 
from the femoral vein whose flow is directed into the area 
of potential PFO). Definition of other risk factors associated 
with paradoxical embolism (e.g. a gradient favoring right to 
left shunt, presence of Eustachian valve or Chiari strands) 
should heighten one’s suspicion that closure of an interatrial 
communication could render substantial benefit in alleviating 
the occurrence of migraine, and lead to a resolution or marked 
decrease in symptoms.
Currently, definitive evidence from prospective rand-
omized clinical trials establishing the benefit of PFO or ASD 
closure for migraine headache is still lacking. The results of the 
first such randomized trial (MIST) were initially presented at 
the ACC Meeting (March 2006)35 and just recently published.36 
The MIST trial studied 147 patients with migraine and a PFO 
who were randomly assigned to sham treatment (n=73) or 
PFO closure (n=74). At 6 months 50% reduction in headache-
days frequency was achieved by 42% of patients who had the 
PFO closed versus 23% in the sham arm. However, the primary 
end-point, complete elimination of headache, was achieved by 
only 3 patients in each group. More randomized trials, such 
as the MIST-2, ESCAPE (Effect of Septal Closure of Atrial 
PFO on Events of Migraine with Premere), FORMAT (Patent 
Foramen Ovale Closure to Reduce Migraine Attacks), and 
the PREMIUM trial (Prospective Randomized Investigation 
to Evaluate Incidence of Headache Reduction In Subjects 
with Migraine & PFO Using the Amplatzer PFO Occluder 
Compared to Medical Management) are currently in progress, 
which are anticipated to render further knowledge about the 
benefit of percutaneous PFO closure on the occurrence and 
severity of migraine headaches.
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